| Literature DB >> 19925969 |
Paul-Henri Lambert1, Tony Hawkridge, Willem A Hanekom.
Abstract
The only currently licensed tuberculosis (TB) vaccine, bacille Calmette Guérin, confers incomplete protection against tuberculosis, and is not safe in infants infected with the human immunodeficiency virus. A new, safe vaccine regimen, which better protects against lung disease, is urgently needed to control TB in high-burden countries. Multiple candidate vaccines have shown promise in preclinical studies, and are now entering phase 1 to 2B clinical trials. This article discusses progress in the field and issues surrounding safety, reactogenicity, immunogenicity, and efficacy testing of new TB vaccines.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19925969 DOI： 10.1016/j.ccm.2009.08.014
Source DB: PubMed Journal: Clin Chest Med ISSN： 0272-5231 Impact factor: 2.878